1. Home
  2. Directory
  3. Pennsylvania
  4. Camp Hill
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1356333751

MARY A. SIMMONDS MD
Prescription History 1356333751
Internal Medicine - Hematology & Oncology in Camp Hill, PA

NPI Status: Active since August 22, 2005

Contact Information

3912 TRINDLE ROAD
CAMP HILL, PA
ZIP 17011
Phone: (717) 761-8740
Fax: (717) 761-8792

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MARY A. SIMMONDS MD, an active Hematology & Oncology specialist practicing in Camp Hill, PA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 80 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 45 claims alone.

Medication Index

A
H
L
T
No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 45
30-Day Fills 113.3
Days Supply 3,400
PA State Average Benchmarks
Peer Average Claims69.0
Peer Average 30-Day Fills155.9
Peer Average Days Supply4,637
Conservative Utilization

This provider writes prescriptions for this formulation 34.8% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,451.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.26

State Avg Cost Per Claim

$27.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 20.8
Days Supply 624
PA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills60.0
Peer Average Days Supply1,765
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $275.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.08

State Avg Cost Per Claim

$33.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Letrozole

Generic Formulation: LetrozoleSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 36.0
Days Supply 1,080
PA State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills100.1
Peer Average Days Supply2,980
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.9% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $491.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$40.95

State Avg Cost Per Claim

$26.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 36.0
Days Supply 1,080
PA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills69.5
Peer Average Days Supply2,063
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.5% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $743.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$61.94

State Avg Cost Per Claim

$32.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MARY A. SIMMONDS MD provides transparency into local medical care patterns within Camp Hill, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.